News

Net profit of Titan Biotech rose 66.17% to Rs 6.73 crore in the quarter ended March 2026 as against Rs 4.05 crore during the previous quarter ended March 2025. Sales rose 38.84% to Rs 48.83 crore in the quarter ended March 2026 as against Rs 35.17 crore during the previous quarter ended March 2025.For the full year,net profit rose 38.83% to Rs 29.89 crore in the year ended March 2026 as against Rs 21.53 crore during the previous year ended March 2025. Sales rose 31.79% to Rs 206.19 crore in the year ended March 2026 as against Rs 156.45 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales48.8335.17 39 206.19156.45 32 OPM %19.8912.99 -18.7216.25 - PBDT11.585.87 97 43.1028.54 51 PBT10.285.03 104 38.1724.37 57 NP6.734.05 66 29.8921.53 39 Powered by Capital Market - Live News

Titan Biotech announced that the Board of Directors of the Company at its meeting held on 30 May 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 25%) , subject to the approval of the shareholders.

Titan Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2026.

Net profit of Titan Biotech rose 94.31% to Rs 8.53 crore in the quarter ended December 2025 as against Rs 4.39 crore during the previous quarter ended December 2024. Sales rose 47.62% to Rs 56.51 crore in the quarter ended December 2025 as against Rs 38.28 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales56.5138.28 48 OPM %19.1612.67 - PBDT11.836.29 88 PBT10.565.10 107 NP8.534.39 94 Powered by Capital Market - Live News

Titan Biotech will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live News